top of page
추상적인 검은 파도
GR-topbg copy.jpg
recombinant Botulinum Toxin concept image

Recombinant Botulinum Toxin

Setting a new benchmark for next-generation toxin therapies through recombinant BoNT engineering

Targeted mRNA Delivery

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

The Next Frontier in Biotech

MVRIX is a biotechnology company focused on advancing new possibilities beyond the limits of conventional medicines.

main_bg01.png

The Next


Frontier


in Biotech

MVRIX는 첨단 바이오 기술을 통해 기존 의약품의 한계를 뛰어넘어 새로운 가능성을 열어가는 혁신적인 연구를 수행하는 기업입니다

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

We advance next-generation gene therapies through targeted mRNA delivery and in vivo CAR-T innovation.

We go beyond existing limits

to provide better choices

through Innovative R&D

3

Platform Technology

80

Patents

20 +

Collaborative partners

bg_maintech_exp.jpg

Our Technology

Smarter Innovation

We lead the future of therapeutics with three protein-engineering platforms.

Science 01
Navibody Platform

A targeted mRNA delivery platform that enhances antibody–LNP specificity and improves production efficiency.

  • In vivo CAR-T

  • Navibody Service

Science 02
rBoNT Platform

A recombinant botulinum toxin platform based on engineered recombinant production, enabling faster and safer development.

  • Faster, Longer rBoNT(Cosmetics)

Science 03
Virucidal Platform

A virucidal platform based on validated rHDL production technology, designed to address enveloped viruses such as COVID-19, influenza, and mpox.

  • Anti-COVID-19

Latest News

MVRIX in motion

We capture and share the moments of change we are creating.

11/5/25
Bio-Europe 2025 참가
6/11/25
Attended Plaque award ceremony(2025 Super-Gap Startup 1000+ DIPS Project)
5/20/25
MVRIX signs MBT-002 licensing deal with Eyegene
4/16/25
Selected for 2025 Super-gap Company in Biopharma & Materials

Our Partners

Growing Synergy

MVRIX grows through strategic partnerships and collaboration.

Press Release

Reaching Further

Discover the latest updates from MVRIX.

default
엠브릭스, 유전자 치료제용 전달 플랫폼 美 특허 등록

12/16/25

한국경제

default
[초격차 스타트업] 엠브릭스 대표 정상원 "앞으로 4년 후 IPO 추진, 신약 개발이 목표"

6/27/25

Business post

default
[인터뷰] ‘스타트업 1000+’ 지원사업 선정된 엠브릭스 정상원 대표

6/25/25

Kyeongin Ilbo

default
KIT '바이오헬스 신약·소재 분야 초격차기업' 선정

4/16/25

Kukinews

bottom of page